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TRENDS IN COMPARATIVE EFFECTIVENESS OF TOP 20 HIGHEST 
SELLING DRUGS
Aggarwal S, White N, Stevens C
PAREXEL INTERNATIONAL, Bethesda, MD, USA
OBJECTIVES: The recently made coverage decisions by UK’s NICE, Scotland’s SMC 
and the allocation of $1.1 Billion for comparative effectiveness research by the United 
States, are strong indicators of trends in pricing and reimbursement that are likely to 
be observed in the future. To gain an additional insight into these trends, we analyzed 
the cost effectiveness studies for the top twenty highest selling drugs (^$160B world-
wide sales) METHODS: Drugs were categorized as primary care, specialty, small 
molecules, biologics, therapy areas and availability of generic alternatives. Cost effec-
tiveness Ratios (CERs) published in peer-reviewed journals and technology assess-
ments conducted by payers were used for this analysis. RESULTS: There is a large 
variability in CERs for same drugs for different indications, in some cases also varying 
by biomarkers. Primary care drugs had lower and less variable CERs than specialty 
drugs. For example, CERs for clopidogrel range from $13,000 to $32,000, whereas 
for bevacizumab, it ranged from $125,000 to $350,000. Most striking was the CER 
for epotein alpha, which was ^$55,000 for Hb target levels of 11.0–12.0 g, but 
increased dramatically to $613,015 for target Hb of 12.0–12.5 g. Our analysis of 
‘generic alternatives’ and the ‘new clinical evidence’ shows that previously deemed 
cost effective drugs could be re-assessed as being not cost effective when generics or 
new branded drugs with comparable efﬁcacy become available (e.g. CATIE trial data 
for quetiapine). This would play a major role in the future, as more payers, including 
the US public payer CMS, explore ways to design a continuum in the coverage decision 
making process; implying that updated cost effectiveness ratios could change previ-
ously established coverage policies. CONCLUSIONS: This analysis shows the range, 
variability and methods used for calculation of ICER values for these high budget 
impact drugs and provides lessons for executives and policy makers.
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PRICING AND REIMBURSEMENT (P&R) IN BRIC COUNTRIES
Shepelev J, Richard L
GfK Healthcare, London, UK
OBJECTIVES: To review the procedure and requirements for P&R of pharmaceuticals 
in Brazil, Russia, India and China. METHODS: A review was conducted of the ofﬁcial 
websites of governmental and public health institutions in the countries of interest. 
This review was complemented by interviews with key stakeholders in the respective 
countries. RESULTS: Free pricing of pharmaceuticals exist in general terms in Russia 
and India. In India, free pricing applies to non-scheduled drugs and pricing restrictions 
may be extended to drugs on the National Essential Medicines List. In China, prices 
are ﬁxed by central government; whereas in Brazil external drug pricing is used as the 
major cost-containment measure. In Brazil, hospital drugs are reimbursed if they are 
on the Essential Medicines List and expensive therapies for cancer and chronic diseases 
are provided by the Exceptional Medicines Program. Reimbursement of retail drugs 
is limited to the Popular Pharmacy Program and the majority of costs are covered out 
of pocket. Similarly, the most drugs costs are covered out of pocket in India; with 
only established generics being reimbursed. Russia saw the federal reimbursement 
system, DLO, being introduced in 2005 to provide pensioners, invalids, and patients 
suffering from chronic diseases access to new therapies. In 2008 the DLO program 
was split into two subprograms: the expensive medicines program covering seven 
indications, with the remaining drugs on the DLO list being supplied through the 
ONLS program. In China, innovative drugs are currently negotiated at local level. 
CONCLUSIONS: Although cost-containment measures seen with more traditional 
markets are prevalent in the emerging markets, these markets are still undergoing sig-
niﬁcant changes in their P&R frameworks. Thus, as these markets develop their pro-
cesses further, it will be necessary not only to consider P&R in the context of 
conventional wisdoms but also the political, social and cultural norms underpinning 
these systems.
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POSITIVE DRUG LIST IN BULGARIA—5 YEARS LATER
Ivanova AD1, Petrova GI1, Benisheva—Dimitrova TV2
1Medical University, Faculty of Pharmacy, Soﬁa, Bulgaria, 2Medical University Soﬁa, Faculty of 
Public Health, Soﬁa, Bulgaria
OBJECTIVES: To compare the regulatory framework and the structure of the Positive 
Drug Lists (PDL) in Bulgaria issued in 2003 and 2009.  METHODS: Comparative 
legislation analysis was applied towards the requirements of the newly adopted regula-
tion on PDL in 2008 with the regulation in 2003. It was analysed the requirement to  
the applicants, including the pharmacoeconomic evidences, selection procedure and        
the structure of the PDL. RESULTS: Main changes in PDL regulation are the follow-
ing. In 2003 PDL the medicines were selected according to their innovativeness in one 
list under INN. In 2008 PDL medicines were separated in 4 lists according to the   
ﬁnancing sources—Health Insurance, Hospital, Governmental budget and National       
Health programs. The criteria for the medicines evaluation were increased (efﬁcacy, 
effectiveness, safety and pharmacoeconomic) and detailed in the new regulation. The  
PDL Committee is deciding both reimbursement status and level. The reimbursement 
level is deﬁned on the basis of the international comparison with reimbursement levels 
in 7 reference countries calculated as lowest cost per DDD per unit. The changes in   
the structure of the PDL are the following. In 2003 there were list A with 625 INNs 
and list B with trade names that were updated on a yearly basis. In 2009 the four 
separated lists include 575 INNs presented with their trade names and dosage forms      
together. Reimbursement list 1 include 289 INNs, list 2 (518 INNs), list 3 (101 INNs) 
and list 4–59 INNs. Lots of INNs in all lists are overlapping. Also near 50 combina-
tions are presented in the PDL. CONCLUSIONS: The new PDL includes less INNs 
as a total number and lots are overlapping between the lists. No National pharmac-  
oeconomic guideline exists both for the PDL committee and manufacturers and thus 
no evidences for the inﬂuence of pharmacoeconomics exist.      
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FREE BUT VALUABLE: THE ECONOMIC SIGNIFICANCE OF SERVICES 
PROVIDED BY PORTUGUESE PHARMACIES
Gouveia M1, Machado F1, Mendes Z2
1FCEE, Universidade Católica Portuguesa, Lisbon, Portugal, 2CEFAR-Center for Health 
Evaluation Studies, Lisbon, Portugal
OBJECTIVES: Besides dispensing medicines, pharmacies render other services includ-
ing advice on health problems and on the best use of medicines; detecting problems 
in patients’ medications; counseling on nutrition, etc. The majority of these services 
is free. Up to now, the volume of these services in Portugal were unknown. This paper 
presents 2008 estimates for the volume of pharmacy interventions and their economic 
value. METHODS: The data came from two 2008 surveys. A pharmacy survey was 
designed to estimate the volume and cost of the free interventions in community 
pharmacies in Portugal. In a general population survey, respondents answered a set 
of questions (choice experiments) designed to elicit their willingness to pay for a few 
typical services provided for free at community pharmacies. RESULTS: We estimate 
a total of 38.8 million free pharmacy interventions in 2008, 3.7 interventions per 
inhabitant. The top three pharmacy interventions were advice on non-prescription 
medicines, advice on prescription-only medicines and counseling related to point-of-
care measurements and monitoring (cholesterol, pregnancy, etc.) and they used 2.8 
million hours of work, about 13% of the total hours of work, at a cost of a54 million. 
This cost was equivalent to 20% of the pharmacies’ gross income. We estimated the 
willingness to pay for the three main pharmacy interventions by conjoint analysis. The 
aggregate value of the services provided was estimated at a76.5 million. The net value, 
from society’s perspective, for the three interventions was estimated to be a51 million. 
CONCLUSIONS: We found the volume of services provided at no charge to be sig-
niﬁcant, as were the resulting pharmacies’ costs. The beneﬁts to consumers were even 
larger generating a substantial net beneﬁt to society.
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CONSENSUS OF KEY DECISION MAKERS AND EXPERTS ON THE 
PRESENT AND FUTURE ON THE ASSESSMENT OF HEALTH 
TECHNOLOGIES IN SPAIN
Paz S1, Lizan L2, Rodriguez JM3, Anton E3
1Outcomes’10 Research Group, Castellon, Castellon, Spain, 2Jaume I University, Castellon, 
Spain, 3Medtronic Iberia, Madrid, Spain
OBJECTIVES: Mechanisms for assessing health technologies (HT) have gone through 
major regulatory changes over the last ﬁve years in Spain. This study aims to determine 
the consensus level amongst decision makers and experts on the present and future of      
health technologies’ assessment. METHODS: This is the second part of a two-phase 
study. A sample of participants and experts in HT evaluation was invited to participate 
on a two-round Delphi consultation (phase 2) about the most relevant and controver-
sial issues identiﬁed in phase I. The present situation as well as desirable (D) and fea-          
sible (P) feature scenarios were considered. Consensus was reached when given 
statements were scored 7.5 or higher by 75% or more of the participants. RESULTS: 
Decision makers (n  16) and experts (n     8) participated in the study (mean involve-      
ment length in HT assessment: 12.4 [SD: 7.7] years). Present: Consensus was reached 
on that 1) the absence of established mechanisms to set priorities and deﬁne needs 
(83.3%), and the scarce political support (79.2%) explain the little inﬂuence of current        
legislation on HT implementation; 2) safety and efﬁcacy (79.2%) are always consid-
ered to decide the implementation of HT. Coincidence of opinions existed for the poor 
deﬁnition of decision makers’ roles and responsibilities (70.8%) and the deﬁcient 
management of information between evaluation entities and decision makers (62.5%). 
Future: 1) Importance of value dossier and impact budget estimates (D: 95.8%, P: 
12.5%) to support implementation; 2) efﬁciency and cost-effectiveness data will deter-
mine decisions (D: 91.7%; P: 12.5); 3) beneﬁts for patients (D: 87.5%; P: 41.7%) and 
equity improvements (D: 91.7%; P: 16.7%) will be prioritised; 4) gains on patients’ 
satisfaction, preferences and health related quality of life (HRQL) will deserve special 
attention (D: 75%; P: 12.5%) CONCLUSIONS: An important gap exists between 
desirable (D) and feasible (P) future scenarios. Agreement upon implementation 
mechanisms is mandatory. Patient centred results become relevant.
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QUALITY ADJUSTED LIFE YEARS (QALYS) IN ECONOMIC 
EVALUATIONS OF HEALTH TECHNOLOGIES IN SPAIN: A REVIEW OF 
THE 2003–2009 LITERATURE
Lizan Tudela LV1, Paz S2, Rodriguez JM3, González P3
1Jaune I Unversity, Castellon de la Plana, Castellon, Spain, 2Outcomes’ 10 Research Group, 
Castellon, Castellon, Spain, 3Medtronic Iberia, Madrid, Spain
OBJECTIVES: To appraise economic evaluations of health technologies that included 
QALYs as an outcome measure conducted over the last seven years in Spain.   
METHODS: Economic evaluations that included QALYs as an outcome measure, 
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conducted in Spain and published between January, 2003 and April, 2009 were identi-
ﬁed. A combination of terms was applied to systematically review electronic and grey 
literature sources. Three Spanish journals were hand searched. Methodological quality 
was assessed applying the National Institute of Clinical Excellence (NICE) 10 criteria 
checklist and the Oxford Centre for Evidence Based Medicine (CEBM) recommenda-
tions for appraising economic evaluations. RESULTS: After applying the inclusion 
and exclusion criteria, a total of 48 papers and 1 Health Technologies Evaluation 
Agency (HTEAs) report were included. Key ﬁndings: 1) 69.5% of papers referred to 
therapeutic interventions; 30.4% to preventive strategies; 2) no assessments of diag-         
nostic procedures were identiﬁed; 3)10.4% dealt with medical devices; 4) Markov 
modelling was frequently applied (58.7%); 5) the NHS perspective was commonly 
adopted (56.5%); 6) costs and effects were usually discounted (71.7%); 7) probabi-
listic methods were reported in 36.4% papers; 8) in 91.9%, either the ICER or ICUR 
was stated; 9) effectiveness, costs and utility data came from Spanish sources in 15.2% 
publications; 10) 60.8% of studies were of 3b level of evidence mainly due to the 
diverse nature of the sources consulted to gather data, estimate utilities and design 
models; 11) 89% of authors compared their ﬁndings against an accepted threshold of 
a30,000 per QALY, but little attention was given to contrasting results or addressing 
other implementation issues; 12) 45.6% reported the source of funds. CONCLU-
SIONS: A small number of economic evaluations using QALYs was conducted. 
Diagnostic and preventive interventions as well as medical devices were scarcely con-    
sidered. Low evidence scores show that important methodological limitations remain 
unsolved to produce reliable estimates to guide the allocation of resources.
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PUBLICATION OF COST-EFFECTIVENESS ANALYSES AND 
SUBSEQUENT CITATIONS IN THE MEDICAL AND HEALTH 
ECONOMICS LITERATURE
Greenberg D1, Wacht O2, Neumann PJ1
1Tufts Medical Center, Boston, MA, USA, 2Ben-Gurion University of the Negev, Beer-Sheva, 
Israel
OBJECTIVES: The dissemination of research ﬁndings begins with publication in peer-
reviewed journals and is continued by citation of the original study in other publica-
tions. The number of citations received by an article is one marker of study importance. 
We investigate whether the proliferation of the cost-effectiveness analysis (CEA) litera-
ture in recent years is matched by increased citations of study results. METHODS: 
We used the Tufts Medical Center registry of original CEAs published through 2006 
(www.cearegistry.org) (N  1394) to determine the journal name, and year of publica-
tion. We used the Science Citation Index Expanded (ISI Web of Knowledge, Thomson 
Reuters) to determine the extent to which each CEA has been cited in other publica-
tions. To control for different publication times, we calculated for each article the 
mean number of citations per year since study publication. RESULTS: Citation infor-
mation was available for 1,301 studies (94% of studies analyzed). The average (SD) 
number of citation counts per article was 26 (o 37) (range 0 to 391) and the average        
(SD) number of citations per year since article publication was 3.4 (o 3.9) (range 0 to    
34) and did not vary substantially by year of publication. The ten most cited CEAs 
by number of citations per year since publication were in high proﬁle medical journals 
(e.g., Lancet, New England Journal of Medicine) and were frequently co-authored by 
the most proliﬁc authors of cost-effectiveness research. These studies pertained mainly 
to coronary stents, implantable deﬁbrillators, HPV vaccination, screening and treat-
ment for HIV positive patients. CONCLUSIONS: CEAs are widely published and 
cited, but this phenomenon is not yet accompanied by an increase in citations. Further 
analyses is needed to analyze factors that may contribute to citation of CEAs, as well 
as measures to enhance better dissemination of this important body of research to 
researchers and decision-makers.
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COST-EFFECTIVENESS RESEARCH ON PREVENTIVE MEASURES:  
A SURVEY OF THE PUBLICATIONS IN 2008
van Gils P1, Tariq L2, Verschuuren M1, Van den Berg M1
1National Institute for Public Health and the Environment, Bilthoven, The Netherlands, 
2National Institute of Public Health and the Environment, Bilthoven, The Netherlands
OBJECTIVES: In recent years the literature regarding the cost-effectiveness of disease 
prevention and health promotion has grown exponentially. Aim of this study is an       
analysis of published economic evaluations on prevention: (i) how many economic 
evaluations are published (ii) what type of economic evaluations are published (cost-
effectiveness analyses, cost-utility analyses or cost beneﬁt analysis) (iii) which diseases     
or health problems (WHO-ICD-10 chapters) do economic evaluations of preventive 
interventions focus on (iv) how do those diseases or health problems relate to the 
burden of disease in the Netherlands? and (v) how cost-effective is prevention? 
METHODS: Economic evaluations on preventive measures were identiﬁed by search-
ing PubMed and Scopus. RESULTS: In the calendar year 2008, 232 economic evalu-
ations of preventive interventions are published. In 114 studies the QALY is used as 
outcome measure, in 46 LYS is used and 15 studies present both QALY and LYS. In 
38 studies the outcome measure is ‘cases prevented’. Most economic evaluations focus          
on the prevention of infectious diseases (73), cancers (49), cardiovascular diseases (23) 
and psychological- and behaviour disorders (16). Cardiovascular diseases are respon-
sible for the highest burden of disease (12.5%), followed by psychological- and 
behaviour disorders (11.5%). Of the cost-utility evaluations 84% show an incremental 
cost-effectiveness ratio (ICER) below a50,000 per QALY, of the cost-effectiveness 
evaluations almost 80% show an ICER below a50,000 per LYS. CONCLUSIONS: 
This study shows the disease clusters for which most preventive economic evaluations 
are published, and whether this corresponds with the diseases which cause much 
burden of disease and how cost-effective preventive interventions are. The conclusion        
of our study is that the published economic evaluations correspond rather well with 
the burden of disease in The Netherlands, with exception of infectious diseases and 
cancers. Finally, it appears that almost all published economic evaluations of preven-       
tive measures show favourable cost-effectiveness levels.
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THE PROBLEM-BASED LEARNING AS A NEW PRACTICAL METHOD OF 
SKILL DEVELOPMENT IN THE HEALTH SCIENCES HIGHER EDUCATION
Szögedi-Müller I1, Boncz I2, Betlehem J2, Fekete J1, Kriszbacher I2, Domján P1
1University of Pécs, Zalaegerszeg, Hungary, 2University of Pécs, Pécs, Hungary
OBJECTIVES: The last decade has witnessed a rapid expansion of biomedical knowl-
edge. Despite this, fashions in medical education over the same period have shifted 
away from factual (didactic) teaching and towards contextual, or problem-based,   
learning (PBL). This paradigm shift has been justiﬁed by studies showing that PBL 
improves reasoning and communication while being associated with few if any detect-
able knowledge deﬁcits. METHODS: A retrospective and comparative analytical 
approach was used. Data on ﬁnal Cardiopulmonary Resuscitation (CPR) exam grades, 
collected from PBL or traditionally trained students, and on teaching process, were            
obtained for a total of 2220 students. The data collection took place between 2003–
2008, in two major locations in Hungary and in Finland. The data analysis was done 
with Chi-square and ANOVA using SPSS14.0. PBL and traditional teaching methods          
were compared as well as the schools themselves. RESULTS: Students who received 
PBL training had better ﬁnal CPR exam grades than traditionally trained peers. T-test 
on means yielded signiﬁcant differences (t    3569; p   0.001) between PBL and con-    
ventional training favouring PBL taught students. The only signiﬁcant difference 
among universities was found for PBL training. There was no difference between the 
two universities in terms of ﬁnal CPR grades when traditional training was concerned.           
CONCLUSIONS: It is possible to indicate signiﬁcant differences in the perception of 
the development of problem solving skills between the two countries with the help of 
the khi square trial (khi2  17,974 f  3 p  0.01). The Finnish evaluated the efﬁciency 
of this method, in regard to developing problem solving skills, considerably higher 
than their Hungarian peers. One of the new and important messages of the study is           
to emphasise that the process of learning will not extend in one dimension for the 
whole life, and it will not conﬁned just for the formal school education.
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FIRST IMPRESSIONS FROM A SHORT TRAINING COURSE IN RATIONAL 
USE OF DRUGS FOR THE PHARMACOLOGISTS IN THE PHARMACY 
SCHOOLS IN TURKEY
Toklu HZ1, Dulger G1, Yaris E2, Gumusel B3, Akici A4
1Marmara University School of Pharmacy, Istanbul, Turkey, 2Karadeniz Technical University 
School of Medicine, Trabzon, Turkey, 3Hacettepe University School of Pharmacy, Ankara, 
Turkey, 4Marmara University School of Medicine, Istanbul, Turkey
OBJECTIVES: Pharmacist’ role as patient counsellor/educator in the ambulatory set-
tings is essential for the rational use of drugs (RUD). The need for the qualiﬁed phar-
macy services enforce improvement of teaching methods in pharmacotherapy. 
Pharmacy students often face problems in implementing theorical pharmacotherapy 
knowledge to practice. Thus, novel methods (e.g. Groningen model) are developed for 
pharmacotherapy teaching. METHODS: A short course of “RUD Teaching” was 
conducted. Fifteen pharmacologists from 8 different pharmacy schools (of the total 
13) have attended the 4 day training course. On the ﬁrst day, attendants were subjected 
to a pretest which was based on the evaluation of their dispensing attitudes. For this 
purpose a simulated patient presented a prescription ordering a single drug for the 
treatment of his ailment. Attendants had a 3 day training similar to the Groningen 
model and ﬁnally they were subjected to a posttest. On the last day, trained attendants 
were expected to put their experience into practice with 12 pharmacy students. 
RESULTS: The results have shown that the average dispensing score of the 15 trainees 
(pharmacologists who received the training) which was 32/100 in the pretest, was 
increased to 72/100 at the end of the three days training. The questionnaire showed 
that all of the pharmacology lecturers agreed that the novel teaching method would 
improve the learning efﬁciency and communication skills of the student and change 
their dispensing attitude. On the otherhand 41.6% have stated that they believed the 
new teaching method would produce extra workload to their department. However, 
all of them have claimed that they would practice the new method in their depart-
ments. Also, the students have also stated that the course improved their dispensing 
skills. CONCLUSIONS: Although the course was conducted with a small group of 
trainees, results show that Groningen model can be adapted to RUD teaching in the 
Turkish pharmacy schools.
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DOES THE PROCEDURE MATTER? DIFFERENCES IN THE FUNDING OF 
DRUGS AND MEDICAL SERVICES IN AUSTRALIA
Gallego G, Casey R, Norman R, Goodall S
University of Technology, Sydney, Ultimo, NSW, Australia
OBJECTIVES: The aim of this study was to explore the views and perceptions of 
stakeholder’s about the current national health technology assessment process for new 
